Yusuf Emre Ozdemir1, Meryem Sahin Ozdemir2, Osman Faruk Bayramlar3, Serkan Surme1, Sibel Yildiz Kaya1, Ridvan Karaali1, Ilker Inanc Balkan1, Bilgul Mete1, Nese Saltoglu1, Fehmi Tabak1. 1. Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, 34098, Istanbul, Turkey. 2. Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, 34098, Istanbul, Turkey. sahinmeryem1991@hotmail.com. 3. Department of Public Health, Istanbul Provincial Health Directorate, 34140, Bakırköy, Istanbul, Turkey.
Abstract
BACKGROUND/AIMS: We aimed to explore long-term results of oral antiviral agents in treatment-naïve "HBeAg negative chronic hepatitis B (CHB)" and determine the factors affecting the complete virological response. METHOD: Patients with HBeAg-negative CHB who used oral antiviral agents for at least 3 years were evaluated retrospectively. RESULTS: A total of 173 patients were recorded. The mean duration of treatment was 62.2 ± 28.9 months. Complete virological responses (CVR) were 82.8% (n = 53/64) in tenofovir disoproxil fumarate (TDF), 84.4% (n = 49/58) in lamivudine (LAM), 83.9% (n = 26/31) in entecavir (ETV), 95% in telbivudine (LdT) (n = 19/20) (p = 0.290). Multivariate analysis revealed age ≤ 40 (p = 0.012, 95%CI = 1.38-13.76, OR = 4.36) and baseline HBV DNA value (p = 0.003, 95%CI = 1.23-2.63, OR = 1.78) as independent factors for CVR. Virological breakthrough was detected in 29 (50%) patients on LAM therapy, two (6.4%) patients on ETV therapy, and two (10%) patients on LdT therapy. Treatment was switched to another antiviral agent due to osteoporosis in four patients in the TDF group, muscle pain in nine patients in the LDT group, and headache in one patient in the ETV group. Hepatocelluler cancer was detected in five patients. HBsAg seroclearance developed in two patients. Anti-HBs seroconversion was not detected. CONCLUSION: CVR was achieved at similar rates with all four antiviral agents, while younger age (≤ 40) and low baseline viral load were the main factors for virological response. However, drug resistance and virological breakthrough in the LAM group and side effects in the LdT group were detected during the long-term follow-up. Moreover, HBsAg seroclearance was achieved at very low rates with oral antiviral agents.
BACKGROUND/AIMS: We aimed to explore long-term results of oral antiviral agents in treatment-naïve "HBeAg negative chronic hepatitis B (CHB)" and determine the factors affecting the complete virological response. METHOD: Patients with HBeAg-negative CHB who used oral antiviral agents for at least 3 years were evaluated retrospectively. RESULTS: A total of 173 patients were recorded. The mean duration of treatment was 62.2 ± 28.9 months. Complete virological responses (CVR) were 82.8% (n = 53/64) in tenofovir disoproxil fumarate (TDF), 84.4% (n = 49/58) in lamivudine (LAM), 83.9% (n = 26/31) in entecavir (ETV), 95% in telbivudine (LdT) (n = 19/20) (p = 0.290). Multivariate analysis revealed age ≤ 40 (p = 0.012, 95%CI = 1.38-13.76, OR = 4.36) and baseline HBV DNA value (p = 0.003, 95%CI = 1.23-2.63, OR = 1.78) as independent factors for CVR. Virological breakthrough was detected in 29 (50%) patients on LAM therapy, two (6.4%) patients on ETV therapy, and two (10%) patients on LdT therapy. Treatment was switched to another antiviral agent due to osteoporosis in four patients in the TDF group, muscle pain in nine patients in the LDT group, and headache in one patient in the ETV group. Hepatocelluler cancer was detected in five patients. HBsAg seroclearance developed in two patients. Anti-HBs seroconversion was not detected. CONCLUSION: CVR was achieved at similar rates with all four antiviral agents, while younger age (≤ 40) and low baseline viral load were the main factors for virological response. However, drug resistance and virological breakthrough in the LAM group and side effects in the LdT group were detected during the long-term follow-up. Moreover, HBsAg seroclearance was achieved at very low rates with oral antiviral agents.
Authors: Jordan Feld; Harry L A Janssen; Zaigham Abbas; Andre Elewaut; Peter Ferenci; Vasily Isakov; Aamir G Khan; Seng Gee Lim; Stephen A Locarnini; Suzane K Ono; Jose Sollano; Catherine W Spearman; Chau-Ting Yeh; Man Fung Yuen; Anton LeMair Journal: J Clin Gastroenterol Date: 2016-10 Impact factor: 3.062
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Daniel J Tenney; Ronald E Rose; Carl J Baldick; Kevin A Pokornowski; Betsy J Eggers; Jie Fang; Michael J Wichroski; Dong Xu; Joanna Yang; Richard B Wilber; Richard J Colonno Journal: Hepatology Date: 2009-05 Impact factor: 17.425
Authors: Ching-Lung Lai; Edward Gane; Yun-Fan Liaw; Chao-Wei Hsu; Satawat Thongsawat; Yuming Wang; Yagang Chen; E Jenny Heathcote; Jens Rasenack; Natalie Bzowej; Nikolai V Naoumov; Adrian M Di Bisceglie; Stefan Zeuzem; Young Myoung Moon; Zachary Goodman; George Chao; Barbara Fielman Constance; Nathaniel A Brown Journal: N Engl J Med Date: 2007-12-20 Impact factor: 91.245
Authors: Ching-Lung Lai; Daniel Shouval; Anna S Lok; Ting-Tsung Chang; Hugo Cheinquer; Zachary Goodman; Deborah DeHertogh; Richard Wilber; Richard C Zink; Anne Cross; Richard Colonno; Lori Fernandes Journal: N Engl J Med Date: 2006-03-09 Impact factor: 91.245
Authors: B Ceylan; C Yardimci; M Fincanci; G Eren; U Tozalgan; C Muderrisoglu; Y Akkoyunlu Journal: Eur Rev Med Pharmacol Sci Date: 2013-09 Impact factor: 3.507